Friday 25 June
Today we are excited to announce positive top-line data from our Phase 3 head-to-head trial of trientine tetrahydrochloride and d-penicillamine.
This is the first trial of its kind comparing against the only approved first-line treatment of Wilson’s Disease, d-penicillamine, in more than 70 years.
Dr Karl Heinz Weiss will be presenting this data today at 8.45-9am CEST as part of @EASL | The Home of Hepatology’s International Liver Congress 2021.
